Clinical Trial Update: A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia [Phase 3]

View source ↗

Summary

Phase 3 trial comparing inotuzumab ozogamicin to investigator's choice chemotherapy in relapsed/refractory acute lymphoblastic leukemia has completed with resul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia

Drugs mentioned

• Inotuzumab ozogamicin (inotuzumab ozogamicin)

Snippet

Sponsor: Pfizer | Conditions: Acute Lymphoblastic Leukemia | Phase 3 | Status: COMPLETED | Results posted: 2018-01-17